Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company is headquartered in Cincinnati, Ohio and currently employs 5 full-time employees. The company went IPO on 2022-02-18. The firm owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for ONCO. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: ONCO is a Sell candidate.
ONCO stock price ended at $1.63 on 金曜日, after rising 1.24%
On the latest trading day Jan 16, 2026, the stock price of ONCO rose by 1.24%, climbing from $1.60 to $1.63. Throughout the session, the stock experienced a volatility of 13.61%, with prices fluctuating between a daily low of $1.47 and a high of $1.67. Alongside this price increase, trading volume also rose by 8.7K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 14.6K shares were traded, amounting to a market value of approximately $2.5M.